RMEI Educational Outcomes

View Details

Acute GvHD: Are You Avoiding These Common Treatment Pitfalls?

Allogenic hematopoietic stem cell transplantation (allo-HSCT) can be curative for many patients with hematologic malignancies. However, graft-versus-host disease (GvHD) remains one of the most common complications and one of the leading causes of death after unrelated HSCT. GvHD triples mortality rates.
Presentation Year: 2023
View Details

Refractory or Resistant Cytomegalovirus in Solid Organ Transplant Patients: Overcoming Challenges

Solid organ transplantation (SOT) revolutionized the treatment of organ failure and is a new lease on life for many patients. However, immunosuppressive medications used to prevent organ rejection increase the risk for infections, including cytomegalovirus (CMV). While many antiviral drugs are effective in treating CMV, refractory or resistant infections remain a constant threat.
Presentation Year: 2023
View Details

Emerging Therapies in Kidney Transplantation: What to Watch for in Chronic Active ABMR

Renal transplantation is a potentially life-saving treatment for those with renal failure; however, graft rejection remains a real problem and long-term outcomes remain poor. Although many renal transplants are performed worldwide each year, only a fraction are living with functioning renal grafts, with approximately 40% of renal transplants failing within 10 years.
Presentation Year: 2023
View Details

Refractory & Resistant Cytomegalovirus (CMV) in Solid Organ Transplant: Decision Support Aid

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
Presentation Year: 2022
View Details

Multi-Year Analysis of Transplant Education 2016-2018

Over a 3-year period from 2016 to 2018, RMEI produced 10 live and 5 enduring online medical education courses that addressed optimal strategies for managing AMR and CMV in SOT patients, and CMV in HSCT patients. The education targeted both domestic and international audiences. Key: antibody-mediated rejection (AMR); cytomegalovirus (CMV); hematopoietic stem cell transplantation (HSCT); solid organ transplantation (SOT).
Presentation Year: 2019
Presented at: American Board of Medical Specialties (ABMS)